# Case Report: A case of lymph node metastatic cancer of unknown primary with elevated alpha-fetoprotein achieving long-term survival

**Authors:** Yan Wang, Chao-Qun Wang, Bi-Fei Huang

PMC · DOI: 10.3389/fonc.2025.1724466 · Frontiers in Oncology · 2026-01-05

## TL;DR

A rare case of lymph node metastatic cancer of unknown primary with elevated alpha-fetoprotein achieved long-term survival through personalized treatment.

## Contribution

Demonstrates that individualized treatment strategies can significantly improve prognosis in CUP with unfavorable immunohistochemistry.

## Key findings

- A 67-year-old male with CUP achieved 58 months of survival using a tailored treatment approach.
- Serum alpha-fetoprotein levels correlated with disease activity in this patient.
- Precision medicine and immunohistochemistry are critical for diagnosing and treating CUP.

## Abstract

Carcinoma of unknown primary (CUP) is typically associated with a poor prognosis, with a median survival of less than one year. This article reports a rare case of an alpha-fetoprotein (AFP)-positive CUP patient who achieved a long-term survival of nearly five years, whose diagnostic and therapeutic course offers significant clinical insights.

A 67-year-old male patient presented with left neck lymphadenopathy. A comprehensive workup revealed no primary site, leading to a diagnosis of CUP. Although subsequent immunohistochemistry classified the case into the unfavorable prognostic subgroup, an individualized treatment strategy including three-drug combination chemotherapy based on the clinical suspicion of gastric cancer, targeted therapy with Apatinib, and localized radiotherapy, resulted in a remarkably long overall survival of 58 months. Serum AFP levels closely correlated with disease activity throughout the clinical course.

This case demonstrates that for CUP confined to lymph nodes, active and precisely reasoned individualized treatment can significantly improve prognosis, even in cases categorized as having an unfavorable prognosis. Furthermore, it underscores the necessity of immunohistochemistry for the accurate diagnosis of CUP and suggests that promoting precision medicine strategies may improve outcomes for these patients.

## Linked entities

- **Chemicals:** Apatinib (PubChem CID 45139106)
- **Diseases:** gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}
- **Diseases:** lymph node metastatic cancer (MESH:D009369), gastric cancer (MESH:D013274), lymphadenopathy (MESH:D008206), CUP (MESH:D009382)
- **Chemicals:** Apatinib (MESH:C553458)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12812528/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12812528/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12812528/full.md

---
Source: https://tomesphere.com/paper/PMC12812528